Table 2 The association between FPGS rs1544105 genotypes and patient characteristics (N = 164)
Characteristics | FPGS SNP rs1544105 | p-value* | |
|---|---|---|---|
CC | CT + TT | ||
genotype | genotype | ||
Gender | 1.000 | ||
Male | 9 (62.3) | 95 (63.3) | |
Female | 5 (35.7) | 55 (36.7) | |
Age (years) | 0.336 | ||
<1 | 0 | 0 | |
1-9 | 13 (92.9) | 123 (82.0) | |
≥10 | 1 (7.1) | 27 (18.0) | |
Treatment group | 0.797 | ||
SR | 4 (28.6) | 58 (38.7) | |
MR | 8 (57.1) | 73 (48.7) | |
HR | 2 (1.3) | 19 (12.6) | |
WBC (109/L) | 0.710 | ||
<50 | 11 (78.6) | 125 (83.3) | |
≥50 | 3 (21.4) | 25 (16.7) | |
TEL-AML1 | 0.770 | ||
Positive | 3 (21.4) | 38 (25.3) | |
Negative | 11 (78.6) | 112 (74.7) | |
E2A-PBX1 | 1.000 | ||
Positive | 1 (7.1) | 15 (10.0) | |
Negative | 13 (92.9) | 135 (90.0) | |
BCR-ABL | 0.141 | ||
Positive | 2 (14.3) | 6 (4.0) | |
Negative | 12 (85.7) | 144 (96.0) | |
MLL-AF4 | 1.000 | ||
Positive | 0 | 1 (0.6) | |
Negative | 14 (100.0) | 149 (99.4) | |
Prednisone response | 0.164 | ||
Good | 1 (7.1) | 1 (0.6) | |
Poor | 13 (92.9) | 149 (99.4) | |
CNS involvement | 1.000 | ||
Absent | 14 (100.0) | 148 (98.7) | |
Present | 0 | 2 (1.3) | |